Latest Information Update: 30 Oct 2000
At a glance
- Originator Ranbaxy Laboratories
- Class Antifungals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 30 Oct 2000 Discontinued-Preclinical for Mycoses in India (Unknown route)
- 26 Jul 2000 New profile
- 26 Jul 2000 Preclinical development for Mycoses in India (Unknown route)